pharma · Advanced solid tumors · Advanced Solid Tumors · TTRX
Turn Therapeutics
Turn Therapeutics clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Westlake Village, USA
- Founded
- 2015
- Employees
- 11
- Programs
- 6
- Drugs
- 3
- Patents
- 40
Turn Therapeutics projects
6 ClinicalTrials.gov programs sponsored by Turn Therapeutics.
Turn Therapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
MiLES
Turn Therapeutics
Cancer
1 trial -
GX-03
Turn Therapeutics
Covid19
1 trial -
GX-03
Turn Therapeutics
Eczema Atopic Dermatitis
1 trial -
Repotrectinib (TPX-0005)
Turn Therapeutics
Advanced Solid Tumors
1 trial -
TPX-0005-07
Turn Therapeutics
Advanced solid tumors
1 trial -
CA177-1036
Turn Therapeutics
Phase 1: Advanced solid tumors harboring genetic alterations in MET
1 trial
Frequently asked questions
How many clinical projects does Turn Therapeutics have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.